Pre-made Tefibazumab benchmark antibody (Whole mAb, anti-Staphylococcus aureus fibrin-binding surface epitope clumping factor A (ClfA) therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-Staphylococcus aureus fibrin-binding surface epitope clumping factor A (ClfA) therapeutic antibody (Pre-made Tefibazumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis[1] and of methicillin-resistant S. aureus.[2]
| Products Name (INN Index) | Pre-Made Tefibazumab Biosimilar, Whole Mab: Anti-Staphylococcus Aureus Fibrin-Binding Surface Epitope Clumping Factor A (Clfa) therapeutic antibody |
|---|---|
| INN Name | tefibazumab |
| Target | Staphylococcus aureus fibrin-binding surface epitope clumping factor A (ClfA) |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – kappa |
| VD LC | IgG1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Inhibitex?Inc. (Alpharetta GA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | Staphylococcus aureus fibrin-binding surface epitope clumping factor A (ClfA) |
| Package |
